Jubilant Life Sciences through its subsidiary has received final USFDA approval for Bupropion Hydrochloride extended-release tablets, used for the treatment of major depressive disorder and prevention of seasonal affective disorder. The drug will be made available in strengths of 150 mg and 300 mg. The approved product is the generic version of Wellbutrin XL of Valeant, which is used for the treatment of major depressive disorder and prevention of seasonal affective disorder.
Company Profile : Jubilant Life Sciences Ltd
Leave a Reply